A Study to Assess the Safety Tolerability and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly

  • STATUS
    Not Recruiting
  • End date
    Aug 14, 2023
  • participants needed
    40
  • sponsor
    Ionis Pharmaceuticals, Inc.
Updated on 19 August 2022
octreotide
pituitary
somatomedin c
lanreotide
pegvisomant
cabergoline
pasireotide
insulin-like growth factor
igf1
ionis-ghr-lrx
bromocriptine
gh receptor

Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.

Description

This is a multi-center, open-label, randomized, Phase 2 study of IONIS-GHR-LRx in up to 40 participants with acromegaly. Participants will be randomized to 1 of 3 treatment groups to receive a single dose of IONIS GHR-LRx monthly for 73 weeks. At the end of 73 weeks, participants will enter a 14-week post-treatment (PT) evaluation period.

Details
Condition Acromegaly
Treatment IONIS-GHR-LRx
Clinical Study IdentifierNCT04522180
SponsorIonis Pharmaceuticals, Inc.
Last Modified on19 August 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note